Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

DH80 Jan. 15 at 3:52 AM

$SLS Fam… I have a very strong and admittedly unusual feeling that we may hear something meaningful within the next 7 to 10 days. To be clear—I have no inside information, no specific news, and no unique updates. This is purely intuition. But everything in me says something is coming, and when it does, it could be significant and explosive. I haven’t been on this platform very long, but I’ve been invested in SLS since 2024—less time than some, more time than others. Back then, I entered based on light research and a belief that the risk/reward profile made sense. As time passed, I realized how fortunate I was—not just financially, but philosophically. This feels like one of those rare moments in life where you stumble into both a compelling investment and a meaningful purpose. I truly thank God for the possibility that we may be part of history. I genuinely believe that. To one day tell our children and grandchildren that we were part of a foundational step toward curing cancer—that alone gives me chills. I appreciate every bull here. Someone influenced each of us to join at some point, and along the way, we’ve become more than investors—we’ve become a family. Onward and upward, $SLS!

1 · Reply

kimJongTinyDong Jan. 15 at 3:39 AM

$SLS What will be worth more this summer????

1 · Reply

jhk35611 Jan. 15 at 3:30 AM

$SLS Thanks to the long term gurus (and we all know who they are) I can finally see said the blind man to his deaf wife. It’s about to end gloriously for us. The SLS puzzzle has been put together over the unfair years. Corners were in place and edges too by Phase 1 start. As each trial matured, other pieces started to fit. The big picture began to come into focus. By mid 2025 yall figured out what the puzzle would look like completed. Only a few missing pieces…and the gurus already knew what they looked like and where they go. Just had to wait to get em. Then this week…every PR was called ahead of time and each was a missing piece. We were told which pieces to look for. Our CEO even handed us a few. Seems we’re down to one last piece as JPM conference ends. And as Tony @SellasGPT34bat12 WARNED… it’s a LONG WEEKEND. Market closed til Tuesday. He also says PR in next 3 days. SWEET REVENGE in perfect timing. Go to hell cancer.

1 · Reply

vlucky16 Jan. 15 at 3:27 AM

$SLS Golden Goose!!!

0 · Reply

vlucky16 Jan. 15 at 3:25 AM

$SLS CDK9 inhibitor only one of its kind that is not toxic. Like Keytruda its cancer platform will include 20+ cancers. Unlike Key it's time of use will be much longer. If you used peak revenue 1.5 billion each or just use keys 28 billion peak revenue. 3 x 28= 84 billion BO 435 a share. KNOW WHAT YOU OWN

3 · Reply

MetalFistSlip Jan. 15 at 3:21 AM

$SLS love this analogy moose. Sterg is like Kratos

0 · Reply

vlucky16 Jan. 15 at 3:15 AM

$SLS Let's say SLS GPS trial for AML has a 3 to 5 billion peak revenue valuation due to extended use. Also 3 to 4 other cancers with peak revenue each of 1.5 billion a year each for peak revenue of 5 billion. Total peak revenue 10 billion. As a BO 3x10= 30 billion GPS. 155 a share. Next Post 009

1 · Reply

Stock_Catcher Jan. 15 at 3:02 AM

Treasure Thursday Watchlist Pt. 4 $BYND $BBAI $SLS $QCLS $FJET 850% Runner,950% Runner, let's find a 1000% Runner now.

0 · Reply

Wefel Jan. 15 at 3:01 AM

$SLS Maybe 10$ after 80 event news and before FA? 🤔

1 · Reply

byby1957 Jan. 15 at 3:00 AM

$SLS Great note.. thank you Sellas

0 · Reply

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 16 days ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 5 weeks ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Oct 29, 2025, 5:36 PM EDT - 2 months ago

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Oct 27, 2025, 8:30 AM EDT - 2 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 19, 2025, 9:18 PM EDT - 5 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 5 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 6 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 7 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 8 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 8 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 8 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 8 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 9 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 9 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 10 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 10 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 10 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 11 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 1 year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 1 year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 2 years ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

DH80 Jan. 15 at 3:52 AM

1 · Reply

kimJongTinyDong Jan. 15 at 3:39 AM

$SLS What will be worth more this summer????

1 · Reply

jhk35611 Jan. 15 at 3:30 AM

1 · Reply

vlucky16 Jan. 15 at 3:27 AM

$SLS Golden Goose!!!

0 · Reply

vlucky16 Jan. 15 at 3:25 AM

3 · Reply

MetalFistSlip Jan. 15 at 3:21 AM

$SLS love this analogy moose. Sterg is like Kratos

0 · Reply

vlucky16 Jan. 15 at 3:15 AM

1 · Reply

Stock_Catcher Jan. 15 at 3:02 AM

Treasure Thursday Watchlist Pt. 4 $BYND $BBAI $SLS $QCLS $FJET 850% Runner,950% Runner, let's find a 1000% Runner now.

0 · Reply

Wefel Jan. 15 at 3:01 AM

$SLS Maybe 10$ after 80 event news and before FA? 🤔

1 · Reply

byby1957 Jan. 15 at 3:00 AM

$SLS Great note.. thank you Sellas

0 · Reply

kimJongTinyDong Jan. 15 at 2:55 AM

$SLS when you least expect it.......

0 · Reply

Fishbanger51 Jan. 15 at 2:52 AM

$SLS bringing up the rear...gilead said any new business development must have a significant patient impact and meet a high scientific standard Sounds familiar https://m.youtube.com/watch?v=yQfq5geBe0A

0 · Reply

RealImbackbears Jan. 15 at 2:50 AM

$SLS Yo my wife said today that Stergiou needs to step up his game or she will be leaving me and moving back to puerto rico

1 · Reply

MetalFistSlip Jan. 15 at 2:44 AM

$SLS I’m a pessimist in life. Some bulls have even said I’m too conservative. But I’ve done as much research as possible and truly can’t find a single valid hole in the bullish argument for SLS. If you’re holding … congratulations 🥂

1 · Reply

stockforce123 Jan. 15 at 2:29 AM

$SLS The more you look at this, the more you will realize Sellas has got ALL the Ace cards, from amazing phase 3 data, to numerous historical phase 1, 2 trials on a variety of indications tested with both drugs, world’s best cancer and medical centers, MSK, MD Anderson, Mayo Clinic etc, world’s top AML experts, Scheinberg, Kantarjian, international connections, political relationship on a US-Europe level, Cash on Hand, perfect synergies with BP’s top drugs, Stergiou’s fancy hairdo, and the most important “Selas, the bright light” that is sent down to us. WHAT ELSE for BO bidding?

1 · Reply

RealImbackbears Jan. 15 at 2:26 AM

$SLS Stergiou needs to get more investors.

0 · Reply

jacksparo Jan. 15 at 2:26 AM

$SLS Slight green in the overnight trading season! Enjoy your night my incredible followers and team here. ✅✅!

0 · Reply

Dragonscale Jan. 15 at 2:26 AM

$SLS So now we just wait and Have a little patience. There is only so much DD you can try to find at this end point. We already know

2 · Reply

RemitTekram Jan. 15 at 2:16 AM

$SLS Making deals one step at a time.

0 · Reply

Kittyc803 Jan. 15 at 2:11 AM

$SLS Hey guys . Someone made a fake acct of me . Disregard any follows tx

1 · Reply

Dixie07067 Jan. 15 at 2:07 AM

$SLS I have been critical of the the management previously about how they release news and raise capital, now it's time to understand the science. been here a long time and have taken losses added 25k shares today and truly believe after extensive research we are gonna be on a tear.GLTA

3 · Reply

Atomickb Jan. 15 at 2:04 AM

$SLS - Stooge trying to portray sellanpolous can go alone using Greece national budget . But wall street knows they are 15 nerds who cannot handle the commercial side. One day either a friendly buyout or a hostile bid at 10 $ amd then after some negotiations and nerds being high on greek sangria the price up to 15-20$ .

1 · Reply

Market Cap	591.13M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,891,900
Avg Vol	8,246,652
Day's Range	N/A - N/A
Shares Out	142.44M
Stochastic %K	45%
Beta	2.26
Analysts	Strong Sell
Price Target	$6.83